Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study

被引:16
|
作者
Szekely, Elisabeth [1 ]
Hagberg, Oskar [2 ]
Arnljots, Kristina [1 ]
Jerkeman, Mats [1 ]
机构
[1] Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden
[2] Skane Univ Hosp, Dept Tumor Epidemiol, SE-22185 Lund, Sweden
关键词
Diffuse large B-cell lymphoma; prognostic factors; chemotherapy; incidence; NON-HODGKINS-LYMPHOMA; ELDERLY-PATIENTS; PREDICTIVE MODEL; RITUXIMAB; CHOP; TRIAL; THERAPY; CHEMOTHERAPY; DLBCL; BONE;
D O I
10.3109/10428194.2013.853297
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our aim was to describe a large population-based cohort of diffuse large B-cell lymphoma (DLBCL) during the last decade, evaluating possible improvement in survival and to identify subgroups in need of novel treatment strategies. The study population encompassed all patients diagnosed with DLBCL in Sweden from 2000 through 2010. Altogether 5349 patients were identified. There was no increase in incidence for females, but for males there was an estimated yearly increase in incidence by 0.019 per 10 000. When adjusted for age and gender, the improvement in overall survival for the whole group was estimated at 4.5% per year, most prominent in the age group 60-78 years, and in patients with good performance status. In this large dataset, we were able to detect a clear improvement in overall survival in DLBCL, although restricted to specific prognostic subgroups, and to identify specific disease presentations that significantly affect overall survival.
引用
收藏
页码:1838 / 1843
页数:6
相关论文
共 50 条
  • [1] The impact of age on survival of diffuse large B-cell lymphoma - a population-based study
    Hedstrom, Gustaf
    Hagberg, Oskar
    Jerkeman, Mats
    Enblad, Gunilla
    ACTA ONCOLOGICA, 2015, 54 (06) : 916 - 923
  • [2] Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study
    Melen, Christopher M.
    Enblad, Gunilla
    Sonnevi, Kristina
    Junlen, Henna Riikka
    Smedby, Karin E.
    Jerkeman, Mats
    Wahlin, Bjoern Engelbrekt
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (04) : 614 - 622
  • [3] Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma
    Olszewski, Adam J.
    Winer, Eric S.
    Castillo, Jorge J.
    LEUKEMIA RESEARCH, 2014, 38 (08) : 866 - 873
  • [4] Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the OncoCollect Lymphoma Registry
    Nair, Reena
    Bhurani, Dinesh
    Rajappa, Senthil
    Kapadia, Asha
    Reddy Boya, Rakesh
    Sundaram, Subramanian
    Menon, Hari
    Raman, Ganapathi S.
    Seshachalam, Arun
    Nimmagadda, Ramesh
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [5] A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry
    Gang, Anne O.
    Pedersen, Michael
    d'Amore, Francesco
    Pedersen, Lars M.
    Jensen, Bo A.
    Jensen, Paw
    Moller, Michael B.
    Mourits-Andersen, Hans T.
    Pedersen, Robert S.
    Klausen, Tobias W.
    Brown, Peter de N.
    LEUKEMIA & LYMPHOMA, 2015, 56 (09) : 2556 - 2562
  • [6] Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study
    Huang, Hong-Hui
    Xiao, Fei
    Chen, Fang-Yuan
    Wang, Ting
    Li, Jun-Min
    Wang, Jian-Min
    Cao, Jun-Ning
    Wang, Chun
    Zou, Shan-Hua
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (03) : 473 - 478
  • [7] The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma
    Yang, Yan
    Wang, Lanlan
    Ma, Yanna
    Han, Tingting
    Huang, Mei
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2017, 353 (05) : 459 - 465
  • [8] Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes
    Sun, Yao
    Joks, Monika
    Xu, Li-Ming
    Chen, Xiu-Li
    Qian, Dong
    You, Jin-Qiang
    Yuan, Zhi-Yong
    ONCOTARGETS AND THERAPY, 2016, 9 : 2069 - 2080
  • [9] Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study
    Wasterlid, Tove
    Hartman, Linda
    Szekely, Elisabeth
    Jerkeman, Mats
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (02) : 151 - 157
  • [10] Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma
    Han, Ying
    Yang, Jianliang
    Liu, Peng
    He, Xiaohui
    Zhang, Changgong
    Zhou, Shengyu
    Zhou, Liqiang
    Qin, Yan
    Song, Yongwen
    Sun, Yan
    Shi, Yuankai
    ONCOLOGIST, 2019, 24 (11) : E1251 - E1261